PLPC vs AMPH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PLPC · Preformed Line Products$246.78 ▼ 8.86%
AMPH · Amphastar Pharmaceuticals$28.25 ▲ 0.50%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PLPC +26.8%
- AMPH +5.8%
Head to head
| Metric | PLPC | AMPH |
|---|---|---|
| Price | $246.78 | $28.25 |
| Change today | ▼ 8.86% | ▲ 0.50% |
| Market cap | $1.20B | $1.20B |
| Return, 3 months | -39.3% | +31.3% |
| Return, year to date | +19.7% | +5.5% |
| Return, 1 year | +30.5% | +8.6% |
| P/E (TTM) | 20.7 | 13.0 |
| P/B | 2.3 | 1.5 |
| P/E percentile vs own 5y | 78th | 35th |
| Dividend yield | 0.34% | – |
| Revenue growth (YoY, latest qtr) | +17.6% | +8.2% |
| Net profit growth (YoY) | +587.9% | +117.7% |
| Gross margin | 32.4% | 46.8% |
| Operating margin | 10.1% | 18.7% |
| Net margin | 7.6% | 13.3% |
| Return on equity | 12.0% | 12.4% |
| Analyst target vs. price | +94.5% | -18.6% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 31 | 54 |
| 30-day volatility | 85.8% | 33.9% |
| Max drawdown, 1 year | -48.6% | -42.6% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AMPH is the largest of the group by market value.
- PLPC has returned the most over the past year.
- AMPH carries the lowest trailing P/E.
- PLPC is growing revenue fastest.
- AMPH keeps the most profit per dollar of sales.
- AMPH has been the calmest stock over the last 30 days.